12:45 PM EDT, 05/29/2025 (MT Newswires) -- Inspira Technologies (IINN) said Thursday it has begun the global commercial rollout of its ART100 system, with deliveries expected to begin in H2 2025.

Designed as an alternative to mechanical ventilation, the ART100 cardiopulmonary bypass system was cleared by the US Food and Drug Administration in May last year.

The company said it was making a "strategic shift to accelerate the commercialization of the [system], while maintaining the development and regulatory pathways of its portfolio of products."

Inspira shares were 22% higher in recent trading.

Price: 0.51, Change: +0.09, Percent Change: +20.62